A systematic literature review of utility weights in wet age-related macular degeneration

References

• World Health Organisation. Priority eye diseases: age related macular degeneration. Geneva: World Health Organisation (WHO), 2013. http://www.who.int/blindness/causes/priority/en/index8.html. Accessed March 6, 2013
   Google Scholar
• Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006;4:97
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. NICE, 2013. London, UK. http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed August 13, 2013
   Google Scholar
• Aspinall PA, Hill AR, Dhillon B, et al. Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration. Br J Ophthalmol 2007;91:766–72
   PubMed Web of Science ®Google Scholar
• Bansback N, Czoski-Murray C, Carlton J, et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 2007;16:533–43
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000;35:127–33
   PubMed Web of Science ®Google Scholar
• Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47–51
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120:481–4
   PubMedGoogle Scholar
• Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc 2005;103:173–84, discussion 184–6
   PubMedGoogle Scholar
• Czoski-Murray C, Carlton J, Brazier J, et al. Valuing condition-specific health states using simulation contact lenses. Value Health 2009;12:793–9
   PubMed Web of Science ®Google Scholar
• Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005;46:4016–23
   PubMed Web of Science ®Google Scholar
• Finger R, Hoffmann AE, Fenwick EK, et al. Patients’ preferences in treatment for neovascular age-related macular degeneration in clinical routine. Br J Ophthalmol 2012;96:997–1002
   PubMed Web of Science ®Google Scholar
• Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol 2003;87:8–12
   PubMed Web of Science ®Google Scholar
• Butt T, Dunbar HM, Morris S, et al. Patient and public preferences for health states associated with AMD. Optom Vis Sci 2013;90:855–60
   PubMed Web of Science ®Google Scholar
• Lee BS, Kymes SM, Nease RF Jr, et al. The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology 2008;115:898–903
   PubMed Web of Science ®Google Scholar
• Boland MRS, Vingerling J, Groot M. The burden of age-related macular degeneration in the Netherlands. Poster presented at 14th International Society for Pharmacoeconomics and Outcomes Research annual European congress, Madrid, Spain, 5--8 November 2011
   Google Scholar
• Lotery A, Xu X, Zlatava G, et al. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 2007;91:1303–7
   PubMed Web of Science ®Google Scholar
• Pauleikhoff D, Scheider A, Wiedmann P, et al. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications.] Ophthalmologe 2009;106:242–51
   PubMed Web of Science ®Google Scholar
• Sahel JA, Bandello F, Augustin A, et al; MICMAC Study Group. Health-related quality of life and utility in patients with age-related macular degeneration. Arch Ophthalmol 2007;125:945–51
   PubMedGoogle Scholar
• Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125:1249–54
   PubMed Web of Science ®Google Scholar
• Hollands H, Sharma S. Update on utilities and cost-utility analyses. Curr Opin Ophthalmol 2006;17:223–7
   PubMed Web of Science ®Google Scholar
• Tosh J, Brazier J, Evans P, et al. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health 2012;15:118–27
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Specification for manufacturer/sponsor submission of evidence. NICE, 2012. London, UK. http://www.nice.org.uk/media/F02/9F/SpecificationForManufacturerSponsorSubmissionOfEvidenceJune2012.doc. London, UK. Accessed March 6, 2013
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Guidance on the use of photodynamic therapy for age-related macular degeneration. Technology appraisal 68. NICE, 2003. London, UK. http://www.nice.org.uk/nicemedia/live/11512/32728/32728.pdf. Accessed August 8, 2013
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. Technology appraisal 155. NICE, 2008. London, UK. http://www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf. Accessed August 8, 2013
   Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36
   PubMed Web of Science ®Google Scholar